MRK
A little less Merck, same old Merck
Ninety One UK Ltd just shaved down its Merck & Co. stake, unloading 14,696 shares and ending the quarter with 118,890 shares worth roughly $12.51 million. In fund-manager language, that’s a polite little “we’re still in, just less in.”
Why investors care
On its own, this isn’t the kind of move that sends a stock into a tailspin. But when a notable holder trims exposure, it can hint at portfolio rebalancing, profit-taking, or just a manager deciding Merck has become a slightly smaller slice of the pie.
That said, Merck’s backdrop is still doing Merck things:
- It beat Q4 expectations with $2.04 in EPS versus $2.01 expected
- Revenue came in at $16.40 billion, up 5% year over year
- Management guided FY2026 EPS to $5.00–$5.15
- And it keeps paying that quarterly dividend, now $0.85 a share
The bigger picture
This is less about one fund’s trim and more about the tug-of-war around a mega-cap pharma name: steady cash flows, decent growth, and enough pipeline/regulatory news to keep investors interested, even if one money manager decides to take a little off the table.
Big picture: Merck isn’t flashing panic signs — but in a market this twitchy, even small stake changes can feel like a raised eyebrow.